TY - JOUR
T1 - A case of hyperammonemic encephalopathy in a patient with recurrent colon cancer treated with modified FOLFOX6
AU - Teraishi, Fuminori
AU - Suzuki, Takeo
AU - Nakamoto, Masako
AU - Chikuba, Akira
AU - Nezu, Masashi
AU - Shimamura, Hiroshi
AU - Watanabe, Takamasa
AU - Matsuda, Tadakazu
AU - Takiue, Takao
AU - Chikuba, Hiroshi
PY - 2009/5
Y1 - 2009/5
N2 - FOLFOX therapy is a commonly used chemotherapeutic regimen against recurrent and unresectable colon cancer. However, its acute neurotoxicity is rare and not well recognized. We herein report a case of mFOLFOX6-induced hyperammonemic encephalopathy in a patient having recurrent colon cancer. A 74-year-old female with a history of sigmoid colon cancer was diagnosed as liver, lung, and peritoneal recurrences by surveillance CT and PET/CT. She was initially treated with modified FOLFOX6 therapy. After completing treatment, she presented with sudden onset of confusion, cognitive disturbances, and repeated seizures. None of the other radiographic examinations and laboratory tests provided an explanation for her symptoms except hyperammonemia. She was treated with branched-chain amino acid solutions and high-volume drip infusion, 6 hours after which the encephalopathy resolved. Clinicians should be aware of the adverse hyperammonemia induced by mFOLFOX6 when patients treated with mFOLFOX6 present with neurological disorders.
AB - FOLFOX therapy is a commonly used chemotherapeutic regimen against recurrent and unresectable colon cancer. However, its acute neurotoxicity is rare and not well recognized. We herein report a case of mFOLFOX6-induced hyperammonemic encephalopathy in a patient having recurrent colon cancer. A 74-year-old female with a history of sigmoid colon cancer was diagnosed as liver, lung, and peritoneal recurrences by surveillance CT and PET/CT. She was initially treated with modified FOLFOX6 therapy. After completing treatment, she presented with sudden onset of confusion, cognitive disturbances, and repeated seizures. None of the other radiographic examinations and laboratory tests provided an explanation for her symptoms except hyperammonemia. She was treated with branched-chain amino acid solutions and high-volume drip infusion, 6 hours after which the encephalopathy resolved. Clinicians should be aware of the adverse hyperammonemia induced by mFOLFOX6 when patients treated with mFOLFOX6 present with neurological disorders.
KW - Hyperammonemia
KW - mFOLFOX6
KW - Recurrent colon cancer
UR - http://www.scopus.com/inward/record.url?scp=79959814814&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959814814&partnerID=8YFLogxK
M3 - Article
C2 - 19461197
AN - SCOPUS:79959814814
VL - 36
SP - 867
EP - 869
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
SN - 0385-0684
IS - 5
ER -